Israel Englander’s NeuroOne Medical Technologies NMTC Stock Holding History

Israel Englander’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,475	Closed	-$29K	–	7293
2021 Q4	$29K	Sell	2,475 -15,217	-86%	-$246K	﹤0.01%	6571
2021 Q3	$419K	Buy	+17,692	New	+$508K	﹤0.01%	5506

Other funds holding NMTC

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return

Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Israel Englander's NMTC Position: Q1 2022 in Review

Israel Englander sold out of NeuroOne Medical Technologies (NMTC) in Q1 2022, closing a stake of 2,475 shares — an estimated $29K sold.

Israel Englander first reported a position in NMTC in Q3 2021 and held it in 2 quarters. The position peaked at $419K in Q3 2021. 11 funds tracked by Wall St. Rank hold NMTC as of Q1 2022.

Israel Englander reported no remaining NeuroOne Medical Technologies position as of Q1 2022 after selling out during the quarter.
Israel Englander sold 2,475 NeuroOne Medical Technologies shares in Q1 2022, an estimated $29K.
Israel Englander first reported a position in NeuroOne Medical Technologies in Q3 2021 and held it in 2 quarters.
Israel Englander's NeuroOne Medical Technologies position peaked at $419K in Q3 2021.
11 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.